Tarsus Pharmaceuticals (TARS) Amortizatization of Intangibles (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Amortizatization of Intangibles of $849000.0 for Q1 2026, down 35.39% year-over-year from $1.3 million in Q1 2025, and down 8.22% quarter-over-quarter from $925000.0 in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $849000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 35.39% year-over-year to $849000.0; the TTM figure through Mar 2026 stood at $5.0 million (down 4.2% YoY), while the FY2025 annual figure was $5.5 million, up 30.12% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $849000.0, down from $925000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.7 million in Q2 2025, with the low at $63000.0 in Q3 2022.
- The 5-year median for Amortizatization of Intangibles is $1.1 million (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles plunged 90.02% in 2023, then jumped 1084.8% in 2024.
- Tarsus Pharmaceuticals' Amortizatization of Intangibles stood at $1.3 million in 2022, then slumped by 90.02% to $125000.0 in 2023, then surged by 1084.8% to $1.5 million in 2024, then tumbled by 37.54% to $925000.0 in 2025, then fell by 8.22% to $849000.0 in 2026.
- Business Quant data shows TARS's Amortizatization of Intangibles at $849000.0 in Q1 2026, $925000.0 in Q4 2025, and $1.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | 762,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 762,000.00 |
| Mar 31, 2026 | 849,000.00 |
| Dec 31, 2025 | 925,000.00 |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 290,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | 487,000.00 |
| Jun 30, 2023 | 1.07 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 63,000.00 |
| Dec 31, 2021 | 294,000.00 |
| Sep 30, 2021 | -87,000.00 |
| Jun 30, 2021 | 44,000.00 |
| Mar 31, 2021 | 43,000.00 |